Glenmark’s Olanzapine for injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa IntraMuscular Injection 10 mg/vial, manufactured by Cheplapharm Registration GmbH.

 

With this launch, the company enters a market that generated approximately $25.4 million in annual sales for the 12-month period ending May 2026, according to IQVIA sales data for Zyprexa IntraMuscular Injection and its available therapeutic equivalents.

 

Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, “The launch of Olanzapine for Injection underscores our strategic focus on growing a robust injectables portfolio and strengthening our presence within the institutional channel. It reflects our continued commitment to expanding access to quality and affordable treatment options to meet the evolving needs of patients and healthcare providers.”